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Platinum-based chemotherapy has been the cornerstone treatment for small
cell lung cancer (SCLC) for decades, but no major progress has been made
in the past 20 years with regard to overcoming chemoresistance. As the cell
cycle checkpoint kinase 1 (Chk1) plays a key role in DNA damage
response to chemotherapeutic drugs, we explored the mechanisms of
acquired drug resistance to the Chk1 inhibitor prexasertib in SCLC. We
established prexasertib resistance in two SCLC cell lines and found that
DNA copy number, messengerRNA (mRNA) and protein levels of the cell
cycle regulator Wee1 significantly correlate with the level of acquired resis-
tance. Wee1 small interfering RNA (siRNA) or Wee1 inhibitor reversed
prexasertib resistance, whereas Wee1 transfection induced prexasertib resis-
tance in parental cells. Reverse phase protein microarray identified up-reg-
ulated proteins in the resistant cell lines that are involved in apoptosis, cell
proliferation and cell cycle. Down-regulation of CDK1 and CDC25C
kinases promoted acquired resistance in parental cells, whereas down-regu-
lation of p38MAPK reversed the resistance. High Wee1 expression was sig-
nificantly correlated with better prognosis of resected SCLC patients. Our
results indicate that Wee1 overexpression plays an important role in
acquired resistance to Chk1 inhibition. We also show that bypass activa-
tion of the p38MAPK signaling pathway may contribute to acquired resis-
tance to Chk1 inhibition. The combination of Chk1 and Wee1 inhibitors
may provide a new therapeutic strategy for the treatment of SCLC.
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1. Introduction
Small cell lung cancer (SCLC) harbors very frequent
mutations in p53 and Rb, which are key cell cycle
regulators in normal cells [1,2]. In the absence of p53
suppressor activity, SCLC cells mainly rely on the
Ataxia Telangiectasia and Rad3 (ATR)-Checkpoint
Kinase 1 (Chk1) pathway to overcome replication
stress in the event of DNA damage [3,4]. Chk1 is a
vital serine/threonine protein kinase that is responsi-
ble for cell cycle checkpoint-mediated DNA damage
response [5]. In the absence of cell cycle arrest, DNA
damage will not be repaired, and cells will enter
mitosis with damaged DNA that will lead to cancer
cell death [6]. Studies showed that Chk1 also regu-
lates the firing of dormant origins [4], which are initi-
ation zones or clusters of DNA replication [7]. With
impaired Chk1 function, cells can end up in replica-
tion catastrophe because of chromosome instability
[8,9]. Several reports indicate that combining Chk1
inhibition and chemotherapy agents such as platinum,
gemcitabine, pemetrexed, doxorubicin or radiotherapy
has additive antitumor activity in different cancer
types [10,11]. In p53-intact normal or cancer cells,
DNA damage can activate p53, which protects cells
from premature cell cycle progression caused by
Chk1 inhibition [12,13]. Thompson et al. [14] showed
that Chk1 inhibition enhances cisplatin cytotoxicity in
cisplatin-sensitive SCLC cell lines. Byers and col-
leagues have presented promising results using Chk1
inhibition alone or combined with cisplatin in SCLC
xenograft models [15].
The process of cell cycle is rigorous and tightly con-
trolled. The critical components of regulatory systems
are the cyclin-dependent kinase (CDK)/Cyclin com-
plex. The rapid activation of the CDK1/Cyclin B
complex allows the cells to undergo the transition
from G2 to M phase, and this transition is usually
inhibited by Wee1 kinase but promoted by Cdc25
phosphatases. Wee1 is a critical negative regulator of
G2/M transition and belongs to the nuclear serine/
threonine protein kinase family. The human ‘Wee’
protein kinase family consists mainly of Wee1 and
Myt1. Wee1 mainly inhibits the activation of CDK1/
Cyclin B complex by CDK1 phosphorylation (Tyr15),
thus inhibiting cell entry into mitosis. In contrast to
Cdc25 activity, Wee1 can phosphorylate CDK1
(Tyr15), thereby inhibiting the catalytic activity of
CDK1 and block mitotic entry. Thus its activity likely
impacts the sensitivity of cells to Chk1 inhibitor as
well. High expression of Wee1 has been associated
with poor survival and higher recurrence rate in mela-
noma, ovarian carcinoma, gastric cancer and
glioblastoma [16]. The mechanisms of resistance to
Chk1 inhibitors are largely unclear, and acquired
resistance to Chk1 inhibitors has not been investigated
so far. In a recent report, Teicher et al. screened 63
human SCLC lines and three NSCLC lines for
response to 103 anticancer agents approved by the
U.S. Food and Drug Administration and 423 investi-
gational agents. Results showed that agents targeting
nuclear kinases are effective in SCLC lines [17,18].
Besides the activity of Chk1 inhibition in combination
with chemotherapy, Chk1 inhibitor has also been
shown to have antitumor effects as a single agent, by
causing DNA double-strand breaks in S phase and by
promoting premature G2/M transition, leading to
mitotic catastrophe [19]. However, only 15% of a
large panel of cell lines of different tumor types were
sensitive to Chk1 inhibitors; the majority of cell lines
were primarily insensitive (intrinsic resistance). It is
likely that many different mechanisms can lead to the
resistance, such as failure to activate CDK2, even in
the presence of Chk1 inhibition [20].
Here, we explored the potential contribution of
Wee1 to acquired resistance to prexasertib and other
Chk1 inhibitors in SCLC models.
2. Materials and methods
2.1. Cell lines
The human SCLC cell lines GLC4 (obtained from S.
De Jong, Groningen University, Netherlands), H82,
H128, H209, H792 and DMS114 (purchased from
ATCC, Manassas, VA, USA) were cultured in RPMI
1640 medium Glutamax (Thermo Fisher, Waltham,
MA, USA) supplemented with 10% fetal bovine serum
and 1% penicillin-streptomycin at 37 °C in a 5% CO2
incubator. Acquired prexasertib-resistant cell lines
were generated by continuous exposure to drug-
containing medium. The concentration of prexasertib
was titrated up to 1 µM. Resistance levels were deter-
mined by cell viability assays. Mycoplasma testing was
performed regularly using MycoAlert Detection Kit
(Lonza, Walkersville, MD, USA).
2.2. Drugs
Cisplatin was purchased from Sigma (St. Louis, MO,
USA). Prexasertib was provided by Eli Lilly or pur-
chased from MedChemExpress (Monmouth Junction,
NJ, USA). The prexasertib provided by Eli Lilly was
used to establish acquired-resistant cell lines, evaluate
the characteristics of the resistant cell lines, do the
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inhibition experiments by Wee1 inhibitor and detect
the downstream proteins. All other experiments were
performed with prexasertib purchased from Med-
ChemExpress. Several experiments were performed
using both drugs with superimposable results.
AZD7762, PF477736, RO3306, K3861, THZ1,
BIRB796 and MK1775 were purchased from Sel-
leckchem (Houston, TX, USA).
2.3. Cell viability assay
CellTiter-Glo (Promega, Madison, WI, USA) was
used to measure cell viability. Cells were plated in 96-
wells and treated with drugs for 72 h. The signals were
read by Glomax Multi-detection system (Promega).
The IC50 of each reagent was calculated by CALCUSYN
software (BIOSOFT, Cambridge, UK).
2.4. Western blot analysis
Western blot (WB) was carried out using the SDS/
PAGE system (Bio-Rad, Philadelphia, PA, USA),
including the precast gradient gel 4–20% and
TurboTransfer system, according to the manufac-
turer’s instructions. The intensities of bands were
detected using GENETOOLS software (SynGene, Freder-
ick, MD, USA) and standardized by the intensity of
a-tubulin or b-actin (both antibodies were from
Sigma). All other antibodies used were purchased form
Cell Signaling Technology (Danvers, MA, USA), with
the exception of caspase-2 (EMD Millipore, Burling-
ton, MA, USA), phospho-CDC25A(Ser76) (Abcam,
Cambridge, MA, USA) and phospho-CDK2(Tyr15)
(Novus, Centennial, CO, USA).
2.5. Cell cycle analysis
Cells (3–6 9 105) were seeded in 6-well plates, washed
with cold PBS and fixed with ice-cold 75% ethanol in
PBS. Propidium iodide was added, and DNA content
was measured by FACStar plus (Becton Dickinson,
Franklin Lakes, NJ, USA) and analyzed by the Mod-
Fit LT program.
2.6. siRNA knockdown and plasmid transfection
Cells were transfected with specific small interfering
(si)RNA for Wee1, CDK1, CDC25C or scrambled
siRNA (Dharmacon, Lafayette, CO, USA) using Lipo-
fectamine RNAiMAX (Thermo Fisher) for 24 h, prior
to treatment with designated drugs. A number of main
experiments were also performed with a different pool
of siRNA for Wee1 (Santa Cruz, Santa Cruz, CA,
USA). The concentration of the siRNA used for trans-
fection is 40 nM. The siRNA sequences are available in
Table S1. The Wee1 plasmid was obtained from Ori-
gene (Rockville, MD, USA) and transfected using X-
tremeGENE DNA transfection reagent (Sigma) or the
Cell Line Nucleofector Kit with Nucleofector Device
(Lonza) according to the manufacturer’s protocol.
2.7. DNA copy number assay
DNA copy number variation (CNV) analysis was per-
formed using TaqMan DNA copy number assay kit
(Thermo Fisher) according to the manufacturer’s pro-
tocol. RPPH was used as the reference gene. Results
were analysed by COPY CALLER v2.1 (Roche, Man-
nheim, Germany).
2.8. qRT-PCR
Total RNA was extracted using Allprep DNA/RNA
mini kit (Qiagen, Germantown, MD, USA) and qRT-
PCR was performed using the QuantiTect SYBR
Green RT-PCR Kit (Qiagen). All procedures were per-
formed on the ABI 7900HT Fast Real-Time PCR Sys-
tem according to the manufacturer’s instructions. All
primers data are described in Table S2.
2.9. Tissue microarray and
immunohistochemistry
We used a tissue microarray (TMA) containing 157
cases of resected SCLC, described before [21]. The
procedures for immunohistochemistry (IHC) have also
been previously described [22]. All primary antibodies
were obtained from Cell Signaling Technology. Two
independent pathologists (B.K. and J.C.) reviewed the
stained slides in a blinded fashion. The percentages of
tumor cells with positive staining to Wee1 or Chk1
(from 0% to 100%) were used to calculate mean Wee1
and Chk1 expression scores. The median was used as
the cutoff value for Chk1, and the optimal value
obtained from the ROC curve was used as the cutoff
value for Wee1.
2.10. Reverse phase protein microarray
The parental and resistant cell lines of H792 and
GLC4 cells were collected before and after treatment
with 100 nM prexasertib for 24 h, washed with cold
PBS twice, and then placed on dry ice and later
assayed by reverse phase protein microarray (RPPA);
details of the method are described elsewhere [23].
Arrays were probed with a total of 159 antibodies, of
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which 122 were phospho-specific proteins (listed in
Table S3).
2.11. Statistical analysis
Statistical analyses were determined by t-test or one-
way ANOVA using GRAPHPAD PRISM V5.0 (GraphPad
Software, La Jolla, CA, USA). Data were expressed as
mean  SD. All P-values were two-sided and were
considered statistically significant if below 0.05. The
Combination Index (CI) between two drugs was calcu-
lated by CALCUSYN using the Chou–Talalay method
[24], which defines additive effect (CI = 1), synergism
(CI < 1) and antagonism (CI > 1).
3. Results
3.1. Establishment and characterization of SCLC
cell lines with acquired resistance to prexasertib
Two SCLC cell lines, NCI-H792 (p53 mut, Rb wild-
type) and GLC4 (p53 mut, Rb mut), were exposed to
increasing concentrations of prexasertib (from 100 nM
to 1 µM) for over a period of at least 3 months. We
obtained two acquired-resistant SCLC cell lines,
H792LYR and GLC4LYR, with IC50 for prexasertib
of 6828 and 5200 nM, respectively, which are more
than 100 and 500 times higher than those of the paren-
tal cells (50 nM for H792 and 10 nM for GLC4)
(Fig. 1A,B). Compared with their parental cells, the
acquired-resistant cells had a longer doubling time:
34.3 (H792LYR) vs. 26.1 h (H792), and 30.7
(GLC4LYR) vs. 23.3 h (GLC4) (Fig. 1C,D). The prex-
asertib-resistant cells were also resistant to other Chk1
inhibitors – PF477736 and AZD7762 (Fig. S1), indi-
cating cross-resistance. In the cell cycle analysis, the
untreated parental cells had a smaller percentage of
G2/M cells compared with the untreated resistant cells.
As Chk1 inhibition leads to apoptosis in S phase
[25,26], prexasertib treatment caused significant cell
cycle arrest in S phase in the parental cells, at the cost
of significant reduction in G0/G1 cells, followed by a
relative increase in the G2/M phase at later time
points; in the resistant cells, there was no significant
difference between untreated and treated cells and the
percentage of cells in the different phases remains rela-
tively stable (Fig. 1E,F). Applying Steel’s formula [27],
in both H792 and GLC4 there was an increase of
TG2M in the resistant cells compared with parental
cells. For H792 parental cells, TG1, TS and TG2M
were 10.7, 6.0 and 9.4 h, respectively. For H792-resis-
tant cells, TG1, TS and TG2M were 9.3, 8.7 and
16.3 h, respectively. Similarly, in the GLC4 parental
cells, TG1, TS and TG2M were 10.0, 9.0 and 4.3 h,
respectively. In the resistant cells, TG1, TS and TG2M
were 9.7, 9.8 and 11.2 h, respectively. The extension of
the doubling time in resistant cells was therefore
mainly due to the prolongation of the G2/M phase
(Fig. 1G).
3.2. Prexasertib-induced DNA damage and
apoptosis are reduced in resistant cells
Prexasertib can generate double-stranded DNA breaks,
leading to replication catastrophe. The abundance of
single-stranded (ss) DNA during replication stress
exhausts the available pool of Replication Protein A
(RPA; it protects ssDNA from nuclease), increasing
the likelihood that unprotected ssDNA will be cleaved
by endonucleases [28]. RPA is subsequently replaced
by the DNA recombinase RAD51, which forms
extended helical filaments on the ssDNA [29]. RPA32,
RPA70 and RAD51 were decreased in the parental
cells in a dosage-dependent manner upon prexasertib
treatment, but not in the resistant cells (Fig. 1H). It
has been shown that ataxia telangiectasia mutated
(ATM) regulates chromatin loading of ATM and Rad-
3-related (ATR) under DNA damage [30], and ATR
inhibits replication catastrophe by preventing exhaus-
tion of RPA. We observed that both ATM and ATR
kinases are activated in the resistant cells while prexas-
ertib reduced the expression of ATM and ATR in par-
ental cells (Fig. S2). Furthermore, cleaved PARP,
cleaved caspase 2 and cH2AX were decreased in the
resistant cells compared with the parental cells
(Fig. 1H), indicating that Chk1 inhibition induces less
DNA damage and apoptosis in the resistant cells.
3.3. Increased Wee1 expression contributes to
acquired resistance to prexasertib
Because Wee1 is a known important negative regulator
of G2/M transition and cell cycle checkpoint [31], we
further investigated whether Wee1 might play a key
role in the cell cycle progression of the resistant cells.
The messenger (m)RNA and protein levels of Wee1
were significantly up-regulated in H792LYR and
GLC4LYR cells compared with the parental cells, irre-
spective of prexasertib exposure (Fig. 2A,B). Wee1 is a
critical negative regulatory kinase, which phosphory-
lates and inactivates CDK1 to block G2/M transition.
To determine whether Wee1 plays a causal role in the
resistance to Chk1 inhibitors, we examined the cyto-
toxic effect of prexasertib in combination with the
Wee1 inhibitor MK1775 in acquired-resistant cell lines
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(H792LYR and GLC4LYR) and four additional par-
ental SCLC cells (H82, H128, H209 and DMS114).
The combination of prexasertib and MK1775 resulted
in a synergistic effect in these cells (Fig. 2C,F and
Fig. S3A–C); the addition of MK1775 drastically
improved the sensitivity of the H792LYR and
GLC4LYR cells to prexasertib (approximately 70-fold
from 8415 to 119 nM for H792LYR and 100-fold from
4700 to 33 nM for GLC4LYR). H128 cells expressing
more Wee1 showed better survival under prexasertib
treatment but there was no significant correlation
between RB expression and drug sensitivity. MK1775
alone and in combination with prexasertib caused
reduction of phospho-CDK1(Y15) levels in both prex-
asertib-resistant cells. Accordingly, the mitotic marker
phospho-histone H3 (pHH3) increased when cells were
exposed to the Wee1 inhibitor, and combination of
MK1775 and prexasertib induced cH2AX and PARP
cleavage (Fig. 2G). To confirm the specificity of Wee1
inhibition, we used a different siRNA to knockdown
the Wee1 expression in resistant cells. The results were
similar to those obtained with the Wee1 inhibitor
MK1775. The IC50 for prexasertib decreased over
1000-fold in the resistant cells when Wee1 was


























































































































Fig. 1. Characteristics of parental and prexasertib acquired-resistant SCLC cell lines. Cell viability of parental and prexasertib-resistant SCLC
cell lines: (A) GLC4 and (B) H792. Cells were treated with different concentrations of prexasertib for 72 h and cell viabilities were detected
by CellTilter-Glo. (C) Cell doubling times for H792P and H792LYR cell lines. (D) Cell doubling time for GLC4P and GLC4LYR cell lines. Cells
were seeded in six-well plates, 103 per well, and counted every 24 h for 196 h. Data are represented as mean  SD of three independent
experiments. (E) Cell cycle analysis by PI staining and flow cytometry for H792P and H792LYR cells with or without 50 nM prexasertib
treatment for 24, 48 and 72 h. (F) Quantification of the cell cycle analysis. (G) Histogram shows the different cell cycle phases: TG1, TS and
TG2/M for H792, GLC4 parental and resistant cells, respectively. (H) Cells were treated with prexasertib 50 or 500 nM for 48 h, and
apoptosis or DNA repair response proteins as indicated were detected by WB.
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knocked down (Fig. 2H). WB results also demon-
strated abrogation of G2 arrest (increased pHH3) and
more DNA damage upon knockdown of Wee1
(Fig. S3D). These data suggest that Wee1 plays an
important role in acquired resistance to Chk1 inhibi-
tion.
3.4. Wee1 is amplified in GLC4-resistant cells
The acquired resistance was stable in H792LYR cells
in the absence of prexasertib exposure for more than 4
months (Fig. 3A). In contrast, GLC4LYR became less
resistant after culture in the absence of drug for
30 days, and the IC50 for prexasertib decreased from
4700 to 80 nM (Fig. 3B). Expression of Wee1 also
decreased progressively following the removal of prex-
asertib in the culture of GLC4LYR (Fig. 3C). To
determine whether the reduction of prexasertib resis-
tance was due to clonal expansion of less-resistant
GLC4LYR cell populations, we cloned the cells that
had been off drug for 30 days by the limited dilution
method. Among the clones analyzed, there was a large
variation in their sensitivity to prexasertib, which
inversely correlated with the levels of Wee1 expression
(rho = 0.927, P < 0.001, Spearman test) (Fig. 3D–H).
Several clones retained Wee1 gene amplification and
the number of gene copies correlated with the level of
resistance to prexasertib (rho = 0.865, P = 0.001,
H792P














































































































































































Fig. 2. Wee1 expression is elevated in prexasertib-resistant cells and contributes to acquired resistance. (A) H792 and GLC4 parental and
resistant cells were exposed to prexasertib at the indicated concentrations for 48 h, and then, Wee1 and cell cycle regulated proteins as
indicated were detected by WB. (B) Graphical depiction of Wee1 mRNA expression in H792 and GLC4 parental and resistant cells by qRT-
PCR. Data are presented as mean  SD of three independent experiments. Unpaired and two-tailed Student’s t-test. Cell viability analysis
for (C) H792P, (D) H792LYR, (E) GLC4P and (F) GLC4LYR cells. Cells were exposed to different concentrations of prexasertib, MK1775 or
both for 72 h, and cell viability was detected by CellTiter-Glo. (G) Cell cycle and DNA damage-related proteins were detected by WB in
H792LYR and GLC4LYR cells. Cells were exposed to prexasertib 50 nM or MK1775 1 µM or both as indicated for 48 h, and then the cell
lysate was used in WB analysis. (H) Cell cytotoxicity analysis for siControl or Wee1 siRNA-transfected H792LYR and GLC4LYR cells. Cells
were transfected with siControl or siWee1 by RNAiMAX reagent. At 24 h after transfection, cell viability was detected by CellTiter-Glo.
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Spearman test) (Table S4). These data indicate that
Wee1 amplification does indeed contribute to the
acquired resistance to Chk1 inhibitor in GLC4 cells.
Although we did not observe Wee1 amplification in
H792LYR cells (Fig. S4A), its expression was
significantly higher in H792LYR than in H792P cells
(Fig. S4B,C). Interestingly, the expression of E2F1,
which binds the promoter region of Wee1 to regulate
Wee1 transcription [32], was also higher in H792LYR
than in H792P cells (Fig. S4B,C). The siRNA
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Fig. 3. Wee1 amplification in GLC4-resistant cells is highly correlated with the degree of resistance. Cell viability of H792LYR (A) or
GLC4LYR cells (B) by CellTiter-Glo. Cells were cultured without prexasertib for different time periods as indicated. Data are presented as
mean  SD of three independent experiments. (C) GLC4LYR cells were cultured without prexasertib for different time periods, Wee1
protein expression was detected by WB. (D) Cell cytotoxicity of prexasertib for 19 single clones of GLC4LYR by CellTiter-Glo. (E) Wee1
mRNA expression of 10 GLC4LYR single clones, detected by qRT-PCR. (F) Wee1 DNA copy number of 10 GLC4LYR single clones, analyzed
by DNA copy number assay. (G) 18 GLC4LYR single clones in which Wee1 protein expression was detected by WB. (H) Graphical
representation of the western blot (G) is shown in the bar graph where the band intensity of Wee1 is normalized to the a-tubulin.
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knockdown of E2F1 in H792LYR cells caused a sig-
nificant reduction of Wee1 expression and increased
the sensitivity of the cells to prexasertib (Fig. S4D–F).
Therefore, Wee1 may contribute to the resistance to
Chk1 inhibitor via different mechanisms in different
cells, i.e. by gene amplification or transcriptional up-
regulation.
To further validate the role of Wee1 in Chk1 inhibi-
tor resistance, we examined the sensitivity of GLC4P
cells after transfection with Wee1 expression vector by
electroporation. Cell viability analysis and WB results
indicate that the transfected cells become resistant to
prexasertib compared with parental cells (Fig. 4A,B).
Since the main function of Wee1 is to inhibit CDK1
through phosphorylation, we then asked whether
Wee1-mediated resistance to Chk1 inhibitor was regu-
lated through inhibition of CDK1 activity. We
observed that cells treated with the CDK1 inhibitor
RO3306 or CDK1 siRNA were less sensitive to prex-
asertib (Fig. 4C–F). Compared with prexasertib alone,
the combination of prexasertib and CDK1 siRNA
reduced the DNA damage (Fig. 4G). Interestingly, we
did not observe such DNA damage reduction when we
used the CDK2 inhibitor K3861 (Fig. S5). Whereas
Wee1 phosphorylates Y15 and T14 in CDK1 to inacti-
vate its kinase activity, CDK7, a CDK-activated
kinase (CAK), activates CDK1 by phosphorylating
CDK1 at T161 to promote G2/M transition [33]. In
fact, treatment of GLC4 parental cells with the CDK7
inhibitor THZ1 also led to resistance to prexasertib
(Fig. 4H). These data indicate that prexasertib sensitiv-
ity depends upon CDK1 activation, and Wee1-medi-
ated resistance to Chk1 inhibitor is a result of
dysregulation of CDK1.
3.5. CDC25C plays a role in Chk1 resistance
The G2/M transition is negatively regulated by Wee1
and promoted by CDC25. CDC25C activates CDK1
by dephosphorylating Y15 and T14 residues in CDK1
to promote cell cycle progression, whereas activated
Chk1 induces CDC25C phosphorylation at the S216
site, thereby inhibiting its phosphatase activity [34].
Interestingly, the Chk1-resistant cells H792LYR and
GLC4LYR had much higher levels of phospho-
CDC25C(S216) (inactive form) compared with their
parental cells (Fig. 5A). Furthermore, the levels of
phospho-CDC25C(Ser216) were significantly reduced
in the parental H792 and GLC4 cells but remained
high in the resistant cells after exposure to prexasertib
(Fig. 5A). It is conceivable that CDK1 remains in an
inactive state in the resistant cells due to the lack of
CDC25C phosphatase activity, thus preventing the
cells from entering mitosis even in the presence of
Chk1 inhibitor. Therefore, we further asked whether
CDC25C is required for cell death induced by Chk1
inhibition. Knockdown of CDC25C in H792P and
GLC4P resulted in significant increase of cell viabilities
when treated with prexasertib (Fig. 5B). CDC25C
knockdown in parental cells also mitigated prexas-
ertib-induced DNA damage, evidenced by a reduction
of cH2AX (Fig. 5C). These data suggest that inactiva-
tion of CDC25C may also contribute to the resistance
to Chk1 inhibitor.
3.6. Reverse phase protein assay (RPPA)
identifies P38MAPK as potential contributor to
acquired resistance
To explore other potential contributors to resistance
mechanisms, we used RPPA to perform a broader
based pathway activation analysis and examine protein
changes in H792 and GLC4 parental and resistant
SCLC cell lines, exposed to prexasertib treatment for
24 h. Of importance is that the Wee1 was not included
in the RPPA panel. The heat map (Fig. 6A) shows
resistant cells compared with parental cells: the top 10
up-regulated proteins in the two resistant cell lines are
involved in cell cycle regulation, proliferation and
apoptosis (Table S5). Also, we compared the protein
changes induced by treatment and focused on the top
10 up-regulated proteins in the resistant cell lines (Sup-
Fig. 4. Resistance to Chk1 inhibitor is induced via CDK1 inhibition. (A) Cell viability of GLC4P and GLC4P cells transfected with Wee1
plasmid (GLC4P-T); GLC4P-T cells were transfected by electroporation and analyzed by CellTiter-Glo. (B) Wee1 and cell cycle and DNA
damage-related proteins for H792 and GLC4 parental and transfected cells; parental cells were transfected by electroporation for 48 h and
then exposed to prexasertib 50 nM for another 48 h. Protein expression was detected by WB. (C) GLC4P and (D) H792P cells were
exposed to indicated concentrations of the CDK1 inhibitor RO3306 and prexasertib. Cell viabilities were observed by CellTiter-Glo. (E) H792P
and (F) GLC4P cells were transfected with CDK1 siRNA for 24 h and the cell viability was measured by CellTiter-Glo. (G) CDK1 and DNA
damage marker proteins for H792 and GLC4 parental cells transfected by control siRNA and CDK1 siRNA. The parental cells were
transfected with control siRNA or CDK1 siRNA for 24 h and then exposed to prexasertib 50 nM for another 48 h. Protein expression was
detected by WB. (H) Cell viability of GLC4P cells and cells exposed to the CDK7 inhibitor THZ1 100 nM for 72 h, assessed by CellTiter-Glo.
All data for cell viability test are presented as mean  SD of three independent experiments. Unpaired and two-tailed Student’s t-test.
*P < 0.05; **P < 0.01; ns, not significant.
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porting Information Table S6). We verified the expres-
sion of four phosphorylated proteins by WB: phos-
pho-p38MAPK(T180/Y182), phospho-Akt(S473),
phospho-FOXO1(T24) and phospho-FADD(S194)
(Fig. 6B). We were able to confirm that the expression
of these four phosphorylated proteins was higher in
GLC4LYR cells than in parental cells, and remained
high after exposure to prexasertib. However, we were
unable to confirm this finding in H792 cells (Support-














































































































































1138 Molecular Oncology 15 (2021) 1130–1145 ª 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.



























































Fig. 5. Inactivation of CDC25C contributes to the resistance to Chk1 inhibition. (A) CDC25 homolog family protein expression in H792 and
GLC4 parental and resistant cells. The cells were exposed to indicated concentrations of prexasertib for 48 h and WB was performed.
(B) Cell viabilities for GLC4P and H792P cells by CellTiter-Glo. Cells were transfected with small interfering (si)CDC25C for 24 h to knock
down CDC25C expression and then exposed to different concentrations of prexasertib for 72 h. *P < 0.05. (C) Expression of CDC25C and
other proteins as indicated in H792P and GLC4P cells by WB. Alpha-tubulin was used as a loading control. Cells were transfected with
siCDC25C for 24 h, then exposed to prexasertib 50 nM for 48 h. All data for cell viability test are presented as mean  SD of three
independent experiments. Unpaired and two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ns, not significant.
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phosphorylated proteins, such as p-FOXO1(T24), the
baseline expression in parental and resistant H792 cell
lines is much lower. Furthermore, we detected
p38MAPK and AKT mRNA expression in GLC4 cell
lines. Compared with parental cells, the p38MAPK
mRNA expression was two times higher in GLC4-
resistant cells (P < 0.05) but AKT expression was not
significantly different. No significant differences in
expression of p38MAPK and AKT mRNA were
observed in H792 cell lines (Figs 6C and S6B). Also,
compared with parental cells, after prexasertib treat-
ment, phosphorylated p38MAPK (p-p38MAPK) and
phosphorylated MK2 (p-MK2) protein expression
increased dramatically in resistant cells and p-MK2
increased after exposure to prexasertib (data not
shown). In addition, GLC4-resistant cells became more
sensitive to prexasertib and displayed more cell death
when the p38MAPK inhibitor BIRB796 was added
(Fig. 6D).
3.7. Higher Wee1 expression correlates with
better prognosis and higher Chk1 expression in
resected SCLC patients
To determine whether expression of Wee1 or Chk1
correlates with the prognosis of SCLC patients, we
performed IHC staining of these two proteins using a
TMA containing 149 resected SCLC specimens.
Patients with higher Wee1 expression (> 50% of can-
cer cells) had a better overall survival (median OS: not
reached for Wee1-high group vs. 37.2 months for
Wee1-low patients, P = 0.038) (Supporting Informa-
tion Fig. S7A). Furthermore, Wee1 expression posi-
tively correlated with Chk1 expression (rho = 0.610,
P < 0.001 Spearman t-test) (Fig. S7B) but there was
no significant correlation between Chk1 expression
and overall survival (Fig. S7C).
4. Discussion
Platinum-based chemotherapy has been the corner-
stone treatment for SCLC for decades, but unfortu-
nately no major progress in chemotherapy has been
made after the FDA approval of topotecan, a topoi-
somerase I inhibitor, 20 years ago. The development
of new systemic treatments is crucial in this disease,
which is often widely spread to distant sites at diag-
nosis. Chk1 is a key regulator of the cell cycle and
plays a central role in normal DNA replication,
resolving replication stress, mitosis entry and cytoki-
nesis under DNA damage. Inhibition of Chk1 in the
absence of DNA damage can cause impaired DNA
replication, loss of DNA damage checkpoints, pre-
mature entry into mitosis with highly fragmented
DNA, and cell death via replication catastrophe [19].
High expression of Chk1 is present in many solid
tumors such as breast, ovarian, gastric and colorectal
cancer, and is usually associated with poor progno-
sis. Since the ATR-Chk1 pathway is crucial to over-
come replication stress and for cell cycle arrest in
the event of DNA damage, Chk1 is potentially an
important therapeutic target in tumors, which fre-
quently harbor mutated tumor suppressors such as
p53 and Rb. The sensitivity of tumor cells to the
inhibition of Chk1 has been correlated with basal
levels of and/or induced DNA damage and replica-
tion stress.
Since most chemotherapeutic drugs induce DNA
damage, the attractiveness of Chk1 inhibitors probably
lies mainly in combination with the aim of enhancing
DNA damage induced by chemotherapy or other
drugs that are involved in the DNA damage response
signal network, such as Wee1 inhibitors [35]. The
development of Chk1 inhibitors has been burdened by
toxicity and acquired resistance [36,37]. More specific
Chk1 inhibitors and the use of combinations may
improve these issues; in particular, synergistic combi-
nations with chemotherapeutic agents may theoreti-
cally allow decreasing the dosage for each single agent
[38,39]. Prexasertib is a second-generation ATP-com-
petitive Chk1 inhibitor that is highly selective for the
autophosphorylation at site S296. Prexasertib treat-
ment displayed single agent activity in c-myc overex-
pressing subsets of SCLC cell lines as well as in
combination with cisplatin or the PARP inhibitor ola-
parib [40]. Prexasertib combined with PARP inhibitor
Fig. 6. P38MAPK contributes to acquired resistance in GLC4LYR-resistant cells. (A) RPPA results and heat map. The heat map shows 12
clusters, each of which is in triplicate, showing the relative protein expression levels and profiles in H792 and GLC4 parental and resistant
cells at baseline and after exposure to 100 nM prexasertib for 2 and 24 h. (B) p-P38MAPK(T180/Y182), p-FADD(S194), p-AKT(S473) and p-
FOXO1(T24) protein expression in GLC4 parental and resistant cells. The cells were exposed to indicated concentrations of prexasertib for
48 h and proteins were extracted and subjected to WB. (C) Graphical depiction of P38MAPK and AKT mRNA expression in GLC4 parental
and resistant cells by qRT-PCR. Data are presented as mean  SD of three independent experiments. (D) Cell viability analysis for
GLC4LYR-resistant cells by CellTiter-Glo. Cells were exposed to indicated concentrations of prexasertib with or without a fixed
concentration of 3 µM of the P38MAPK inhibitor BIRB796 for 72 h. Data are presented as mean  SD of three independent experiments.
Unpaired and two-tailed Student’s t-test. *P < 0.05; **P < 0.01; ns, not significant.
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also had a synergistic effect in gastric cancer [41]. At
present, 14 clinical trials of prexasertib are ongoing or
have been completed, most of which are phase I or
phase II studies in colorectal cancer, triple negative
breast cancer, head and neck cancer, and SCLC.
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tolerability in patients with BRCA wild-type high-
grade serous ovarian carcinoma [42].
As with most drugs, resistance is also a major prob-
lem in the development of Chk1 inhibitors. Only 15%
of tumor cell lines responded to the Chk1 inhibitor
MK8776 as a single agent, and primary resistance does
not appear to be due to lack of drug bioavailability or
defects in Chk1. Even the resistant cells still showed
auto-phosphorylation of ser296 after 24 h incubation
with a topoisomerase inhibitor and cultured with Chk1
inhibitor for more than 7 days. The resistance could
be overcome by inhibition of Wee1 [20]. Interestingly,
in SCLC cell lines with primary resistance to the Wee1
inhibitor MK1775, AXL was overexpressed, which led
to activation of the ERK/p90RSK and thus to recruit-
ment of Chk1 as a parallel DNA damage repair path-
way [43].
Our results indicate that Wee1 overexpression plays
an important role in acquired resistance to the Chk1
inhibitor prexasertib and was due to increased Wee1
copy number or enhanced transcription. In the cell
cycle progression, the G2/M transition depends on the
activity of CDK1, which mainly relies on the balance
between the activities of the Wee1 kinase and the
CDC25C phosphatase, and Wee1 and CDC25 tightly
control the molecular switch for this transition. Given
this tight regulation of the DNA Damage Response
(DDR), targeting multiple kinases in this signal path-
way could result in a selective killing of tumor cells,
especially in SCLC, which mostly harbors p53 and Rb
mutations. Combining two or more DDR signal path-
way inhibitors could be a valuable therapeutic strat-
egy. Synergy has been achieved using Chk1 and Wee1
inhibitors together in melanoma, lymphoma, leukemia
and other solid tumors [44,45]. Our results indicate
that the combination of prexasertib and the Wee1 inhi-
bitor MK1775 was able to overcome drug resistance
to Chk1 in SCLC cells, where single agents were inef-
fective.
Overexpression of Wee1 is expected to suppress the
CDK1 activity, leading to cell cycle arrest at the G2
phase. We showed that the resistant cells have a longer
doubling time due to G2 phase extension. SCLC
patients with higher Wee1 tumor expression had a bet-
ter prognosis compared with the patients with lower
expression in a large cohort of resected SCLC patients
in our study. Theoretically, cells with higher Wee1
expression would have a longer doubling time and this
may translate in longer PFS and survival in SCLC
patients, because their tumor grows more slowly.
Yoshida et al. [46] reported similar results in NSCLC
patients, where Wee1 expression was inversely corre-
lated with Ki-67 staining (proliferation).
CDC25C has an opposite effect on CDKs to Wee1.
Our results indicate that CDC25C stays in an inactive
status in resistant cells by maintaining significantly
higher levels of phospho-CDC25C (Ser216) in resistant
cells compared with parental cells, even after treatment
with prexasertib. The phosphorylation at Ser216 of
CDC25C inhibits its phosphatase activity, thus pre-
venting CDC25C from removing the inhibitory phos-
phate Y15 on CDK1, which is essentially an activator
of cell cycle progression, and finally preventing cells
from entering mitosis even in the presence of Chk1
inhibitor. Similar results have been reported in ovarian
cancer cells [47].
We were aware that mechanisms for acquired resis-
tance are multiple and we used a screening approach
to investigate other potential mechanisms that could
explain the Chk1 resistance. We used the RPPA analy-
sis for this screening, and all top 10 up-regulated pro-
teins in resistant cells were involved in apoptosis,
proliferation or cell cycle. Only two proteins,
p38MAPK and TNF-R1, in the top 10 up-regulated
proteins induced by exposure to prexasertib in resis-
tant cells vs. parental cells could be seen in both cell
lines. Our results suggest that p38MAPK may also
play a role in acquired resistance to prexasertib.
Besides the ATR/Chk1 and ATM/Chk2 signal path-
ways, it was reported that in the absence of p53, cells
depend on a third cell cycle checkpoint pathway
involving p38MAPK/MK2 for cell cycle arrest and
survival after DNA damage. In the absence of MK2 in
p53-deficient cells, cytotoxic drug exposure may lead
to elimination of S and G2/M phase checkpoint and
mitotic catastrophe [48,49]. Our results show that
p38MAPK mRNA expression is much higher in resis-
tant cells than in parental cells. The RPPA results
demonstrated that the activated phospho-p38MAPK
in resistant cells increased significantly when exposed
to prexasertib, which could not be observed in paren-
tal cells. The p38MAPK inhibitor BIRB796 was to
some extent able to resensitize the Chk1 inhibitory
activity in resistant cells.
TNF-R1 was the top up-regulated protein induced
by exposure to prexasertib in resistant vs. parental
cells in both cell lines. TNF-1R is the receptor for
TNF and is involved in inducing cell apoptosis via
TRADD and caspases. Further studies are warranted
to confirm these findings and to investigate further the
potential mechanism underlying this overexpression.
5. Conclusions
Our study suggests that Wee1 up-regulation is a major
and novel mechanism of acquired resistance to Chk1
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inhibitors in SCLC. Combination of Chk1 and Wee1
inhibitors may overcome the resistance. Combination
studies of Chk1 inhibitors such as prexasertib and
other agents may lead to synergistic interactions. Com-
binations with immune checkpoint inhibitors may be
of particular interest, given the recent positive results
of atezolizumab in combination with platinum
chemotherapy in SCLC patients with extensive disease
[50].
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